Akero Therapeutics (AKRO) reported a Q4 loss Friday of $0.99, unchanged from a year earlier.
Two analysts polled by FactSet expected a loss of $1.19.
The company did not report any revenue for the quarter ended Dec. 31.
As of year-end, Akero had $797.8 million in cash, cash equivalents, and marketable securities that it expects to be sufficient for funding its current operating plan into 2028.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。